Especially if anti-CD20 therapies need to be switched, for instance, due to disease activity or hypogammaglobulinemia, cladribine could be considered as a treatment option for people with MS and comorbid RA [20–22, 74]. The gene discussed is MS4A1; the disease is myeloid sarcoma.